| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | UPB Upstream Bio, Inc. | Gray Michael | CFO And COO | Sell | 853 | $6.10 | $5,203.30 | -2.9% | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Friedl-Naderer Johanna48 | Chief Commercial Officer | Sell | 145 | $18.33 | $2,657.85 | - | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Kerr Douglas59 | Chief Medical Officer | Sell | 887 | $18.33 | $16,258.71 | -0.5% | - | - | |
| Jun 16, 2026 | KRRO Korro Bio, Inc. | Cerio Jeffrey | General Counsel | Sell | 6,609 | $10.83 | $71,575.47 | -15.8% | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Cox John | CEO &President | Sell | 2,683 | $18.33 | $49,179.39 | -0.7% | - | - | |
| Jun 16, 2026 | KRRO Korro Bio, Inc. | Chappell Todd | Chief Operating Officer | Sell | 3,168 | $10.83 | $34,309.44 | -15.7% | - | - | |
| Jun 16, 2026 | ANIX Anixa Biosciences, Inc. | Titterton Lewis H Jr65 | Director | Buy | 2,836 | $2.64 | $7,487.04 | +0.3% | - | - | |
| Jun 16, 2026 | UPB Upstream Bio, Inc. | Sutherland Everett Rand | Chief Executive Officer | Sell | 2,095 | $6.10 | $12,779.50 | -2.9% | - | - | |
| Jun 16, 2026 | KRRO Korro Bio, Inc. | Vincent Loic A | Chief Scientific Officer | Sell | 3,418 | $10.83 | $37,016.94 | -15.7% | - | - | |
| Jun 16, 2026 | BLTE Belite Bio, Inc | Scholl Hendrik Peter | Chief Medical Officer | Sell | 10,000 | $140.57 | $1,405,729.41 | -4.2% | - | - | |
| Jun 16, 2026 | ADPT Adaptive Biotechnologies Corporation | Robins Harlan S84 | Chief Scientific Officer | Sell | 106,160 | $17.41 | $1,847,941.60 | -3.6% | - | - | |
| Jun 16, 2026 | COAG Hemab Therapeutics Holdings, Inc. Common Stock | Ra Capital Management, L.P.53 | 10% Owner | Buy | 67,669 | $24.97 | $1,689,818.48 | +0.5% | - | - | |
| Jun 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | See Remarks | Sell | 14,396 | $60.95 | $877,436.20 | -20.2% | - | - | |
| Jun 15, 2026 | PHVS Pharvaris N.V. | Modig Berndt | Chief Executive Officer | Sell | 2,291 | $31.07 | $71,173.04 | -0.8% | - | - | |
| Jun 15, 2026 | IMNM Immunome, Inc. | Rosett Max | Chief Financial Officer | Sell | 60,000 | $18.23 | $1,093,800.00 | -52.6% | - | - | |
| Jun 15, 2026 | CORT Corcept Therapeutics Incorporated | Mokari Atabak | Chief Financial Officer | Sell | 40,000 | $81.15 | $3,245,900.05 | -25.9% | - | - | |
| Jun 15, 2026 | XNCR Xencor, Inc. | Montgomery Alan Bruce62 | Director | Sell | 5,064 | $12.31 | $62,337.84 | -24.6% | - | - | |
| Jun 15, 2026 | OCGN Ocugen, Inc. | Johnson-Greene Treerita Essalima | Chief Financial Officer | Buy | 21,000 | $1.23 | $25,830.00 | +4.2% | - | - | |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Link William J Phd | Director | Sell | 12,500 | $62.12 | $776,495.16 | -5.5% | - | - | |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Goodrich Katherine | Director | Sell | 2,954 | $62.08 | $183,384.32 | -57.0% | - | - | |
| Jun 15, 2026 | KROS Keros Therapeutics, Inc. | Bienaime Jean Jacques68 | Director | Buy | 1,000 | $10.19 | $10,190.00 | +6.0% | - | - | |
| Jun 15, 2026 | NKTR Nektar Therapeutics | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 5,538 | $60.71 | $336,211.98 | -26.4% | - | - | |
| Jun 15, 2026 | ARDX Ardelyx, Inc. | Raab Michael56 | President &CEO | Sell | 41,666 | $5.67 | $236,346.22 | -2.4% | - | - | |
| Jun 15, 2026 | QURE Uniqure N.V. | Potts Jeannette | Chief Legal Officer | Sell | 5,237 | $27.67 | $144,907.79 | -3.8% | - | - | |
| Jun 15, 2026 | TBPH Theravance Biopharma, Inc. | Farnum Rhonda52 | SVP, Comm &Medical Affairs | Sell | 13,314 | $16.39 | $218,167.20 | -1.8% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.